Punjab’s health authorities issued an urgent public safety warning this week. The Directorate of Drug Control Punjab ordered immediate stoppage of a specific injectable medicine. Therefore, this Punjab injectable medicine alert covers Injection Pd-Meek 1 mL specifically. This product contains Mecobalamin 500mcg/mL under registration number 040562.
The Drugs Testing Laboratory previously flagged serious quality concerns. Officials declared the product “Adulterated and Standard” following testing procedures. Consequently, authorities initiated a recall covering five specific batches. These include MC26020, MC26021, MC26022, MC26023 and MC26024.
Manufacturing facility inspections revealed the core problem directly. Drug inspectors found batches released before completing mandatory sterility testing. This violated Good Manufacturing Practices requirements clearly. Therefore, authorities cannot currently assure sterility, quality, safety or efficacy for these batches. This creates genuine public health risk potential.
The Provincial Quality Control Board Punjab confirmed the alert’s duration specifically. It will remain active until investigation completion. Further directions will follow once authorities finish their review.
All relevant stakeholders received clear instructions immediately. Pharmacies, medical stores, wholesalers and distributors must stop all related activities. This includes sale, purchase, dispensing, distribution and use entirely. Healthcare facilities and other stock holders face identical requirements.
Additionally, these parties must quarantine existing stock separately. They must also report inventory details to relevant drug inspectors. This applies to both regional inspectors and healthcare facility inspectors specifically.
The notice mandates strict enforcement across the province. Drug inspectors and regulators must ensure proper implementation throughout Punjab. This enforcement follows the Drugs Act 1976 and DRAP Act 2012 specifically. Finally, this Punjab injectable medicine alert demonstrates regulatory commitment to consumer safety, ensuring compromised products don’t reach patients while investigations continue.
